ArticleFrontiers in pharmacology2026

Targeting leukemic stem and progenitor cells expressing different BCR::ABL1 levels: antileukemic activity of asciminib with or without TKIs.

Michele Massimino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.